晚期CKD患儿停用RAAS抑制剂与肾功能加速下降相关
本研究纳入69例前瞻性随访期间停用RAAS抑制剂的CKD患儿(平均eGFR 27 ml/min/1.73 m2),评估停药后血压、白蛋白尿、血钾变化及eGFR斜率。停药后血压和白蛋白尿升高、血钾下降;eGFR下降速度较用药期更快(-3.9 vs -1.5 ml/min/1.73 m2/年,P=0.005),而匹配对照队列继续用药者eGFR斜率无变化。
要点
- 晚期CKD患儿停用RAAS抑制剂后eGFR下降加速(-3.9 vs -1.5 ml/min/1.73 m2/年)。
- 停药后血压和白蛋白尿升高、血钾下降,提示风险标志物恶化。
- 匹配对照中继续用药者eGFR斜率无变化,支持停药与加速下降的关联。
核心结论
- 在晚期CKD患儿中,停用RAAS抑制剂与肾功能下降加速相关。
研究设计与样本
- 前瞻性队列研究(CKiD研究),纳入69例随访期间停用RAAS抑制剂的CKD患儿(67%男性,平均年龄13.7岁,平均eGFR 27 ml/min/1.73 m2)。
- 评估停药后中位6个月的血压、白蛋白尿和血钾变化,并用线性混合效应模型估算停药前中位1.9年和停药后中位1.2年的eGFR斜率。
- 另设匹配对照队列,为继续使用RAAS抑制剂的患者。
主要发现
- 医生报告的停药原因为血清肌酐升高、高钾血症和有症状的低血压。
- 停药后血压和白蛋白尿升高,血钾下降。
- 停药后eGFR下降速度较用药期更快:-3.9 ml/min/1.73 m2/年(95%CI -5.1至-2.6)vs -1.5 ml/min/1.73 m2/年(95%CI -2.4至-0.6),P=0.005。
- 匹配对照队列中继续使用RAAS抑制剂的患者eGFR斜率无变化。
临床怎么用
- 对晚期CKD患儿停用RAAS抑制剂需谨慎权衡,停药后应密切监测血压、白蛋白尿和eGFR变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Although renin-angiotensin-aldosterone system inhibition (RAASi) is a cornerstone in the treatment of children with CKD, it is sometimes discontinued when kidney function declines. We studied the reasons of RAASi discontinuation and associations between RAASi discontinuation and important risk markers of CKD progression and on eGFR decline in the Cardiovascular Comorbidity in Children with CKD study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this study, 69 children with CKD (67% male, mean age 13.7 years, mean eGFR 27 ml/min per 1.73 m2) who discontinued RAASi during prospective follow-up were included. Initial change in BP, albuminuria, and potassium after discontinuation were assessed (median time 6 months). Rate of eGFR decline (eGFR slope) during a median of 1.9 years before and 1.2 years after discontinuation were estimated using linear mixed effects modeling. RESULTS: Physician-reported reasons for RAASi discontinuation were increase in serum creatinine, hyperkalemia, and symptomatic hypotension. After discontinuation of RAASi, BP and albuminuria increased, whereas potassium decreased. eGFR declined more rapidly after discontinuation of RAASi (-3.9 ml/min per 1.73 m2 per year; 95% confidence interval, -5.1 to -2.6) compared with the slope during RAASi treatment (-1.5 ml/min per 1.73 m2 per year; 95% confidence interval, -2.4 to -0.6; P=0.005). In contrast, no change in eGFR slope was observed in a matched control cohort of patients in whom RAASi was continued. CONCLUSIONS: Discontinuation of RAASi in children with CKD is associated with an acceleration of kidney function decline, even in advanced CKD.
引用
- van den Belt SM, Heerspink HJL, Kirchner M, et al. Discontinuation of RAAS Inhibition in Children with Advanced CKD. Clin J Am Soc Nephrol. 2020. PMID: 32253275. doi:10.2215/CJN.09750819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。